Granisol Side Effects

Generic name: granisetron

Medically reviewed by Drugs.com. Last updated on Mar 24, 2025.

Note: This document provides detailed information about Granisol Side Effects associated with granisetron. Some dosage forms listed on this page may not apply specifically to the brand name Granisol.

Applies to granisetron: transdermal patch extended release.

Other dosage forms:

• intravenous solution

Precautions

Check with your doctor if severe nausea and vomiting continue after leaving the hospital or cancer treatment center.

Do not take other medicines containing granisetron (the active ingredient contained in Granisol) while using Sancuso®. Using these medicines together may cause serious unwanted side effects.

Check with your doctor right away if you start to have pain or swelling in your stomach area. These may be signs of a serious stomach or bowel problem.

Check with your doctor right away if you have anxiety, restlessness, a fast heartbeat, fever, sweating, muscle spasms, twitching, nausea, vomiting, diarrhea, or see or hear things that are not there. These may be symptoms of a serious condition called serotonin syndrome. Your risk may be higher if you also take certain other medicines that affect serotonin levels in your body.

Serious skin reactions may occur while using the patch. Check with your doctor right away if you have a skin rash, itching, redness, or any skin irritation while you are wearing the patch.

Do not use a heating pad or heat lamp near the Sancuso® patch. Avoid sunlamps and tanning beds while using this medicine.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Serious side effects of Granisol

Along with its needed effects, granisetron may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking granisetron:

Other side effects of Granisol

Some side effects of granisetron may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

See also:

For healthcare professionals

Applies to granisetron: intravenous solution, oral solution, oral tablet, subcutaneous suspension extended release, transdermal film extended release.

General adverse events

ORAL: The most commonly reported side effects included headache, constipation, and asthenia.

PARENTERAL: The most commonly reported side effects included injection site reactions, constipation, headache, and diarrhea.

TRANSDERMAL: The most commonly reported side effects included constipation, QT prolongation, and headache.^[Ref]

Local

PARENTERAL:

• Very common (10% or more): Any injection site reactions (up to 62%), bruising/hematoma (up to 45%), tenderness (up to 27%), pain (up to 20%), mass/nodule (up to 18%), erythema/redness (up to 17%)
• Common (1% to 10%): Bleeding, induration/swelling, infection at injection site, other
• Frequency not reported: Discoloration, irritation, lipoma, paresthesia, pruritus, rash, reaction, scab, scar, vesicles, warmth

TRANSDERMAL:

• Uncommon (0.1% to 1%): Application site irritation
• Frequency not reported: Application site erythema, application site pain, application site pruritus, application site rash, application site reactions
• Postmarketing reports: Application site burn, application site discoloration, application site urticaria, application site vesicles, patch non-adhesion^[Ref]

Gastrointestinal

ORAL:

• Very common (10% or more): Nausea (up to 20%), constipation (up to 18%), vomiting (up to 12%)
• Common (1% to 10%): Abdominal pain, diarrhea, dyspepsia

PARENTERAL:

• Very common (10% or more): Constipation (up to 22%)
• Common (1% to 10%): Abdominal pain, diarrhea, dyspepsia, gastroesophageal reflux
• Frequency not reported: Pancreatitis

TRANSDERMAL:

• Common (1% to 10%): Constipation
• Uncommon (0.1% to 1%): Dry mouth, nausea, retching
• Frequency not reported: Abdominal pain, diarrhea, vomiting^[Ref]

Nervous system

ORAL:

• Very common (10% or more): Headache (up to 21%)
• Common (1% to 10%): Central nervous system (CNS) stimulation, dizziness, somnolence, taste disorder
• Uncommon (0.1% to 1%): Serotonin syndrome
• Rare (0.01% to 0.1%): Extrapyramidal syndrome, syncope
• Frequency not reported: Autonomic dysfunction, extrapyramidal symptoms, neuromuscular abnormalities

PARENTERAL:

• Very common (10% or more): Headache (up to 14%)
• Common (1% to 10%): CNS stimulation, dizziness, somnolence, taste disorder
• Uncommon (0.1% to 1%): Extrapyramidal reactions, serotonin syndrome
• Rare (0.01% to 0.1%): Extrapyramidal syndrome, syncope

TRANSDERMAL:

• Uncommon (0.1% to 1%): Headache, vertigo
• Rare (0.01% to 0.1%): Dyskinesia, dystonia
• Frequency not reported: Dizziness, extrapyramidal reactions, somnolence, syncope^[Ref]

Drug-induced headache is generally mild. In clinical trials, headache typically resolved spontaneously or was relieved by analgesics.^[Ref]

Other

ORAL:

• Very common (10% or more): Asthenia (up to 18%)
• Common (1% to 10%): Fever

PARENTERAL:

• Very common (10% or more): Fatigue (up to 21%)
• Common (1% to 10%): Asthenia, fever

TRANSDERMAL:

• Frequency not reported: Asthenia, fever^[Ref]

Hepatic

ORAL:

• Common (1% to 10%): ALT elevation, AST elevation, elevated hepatic transaminases, transient ALT increases, transient AST increases

PARENTERAL:

• Common (1% to 10%): ALT elevation, AST elevation, transaminases increased, transient ALT increases, transient AST increases
• Frequency not reported: Elevation of serum transaminase levels

TRANSDERMAL:

• Uncommon (0.1% to 1%): ALT increased, AST increased, GGT increased
• Frequency not reported: Elevated hepatic transaminases^[Ref]

Psychiatric

ORAL:

• Common (1% to 10%): Agitation, anxiety, insomnia
• Frequency not reported: Altered mental status

PARENTERAL:

• Common (1% to 10%): Agitation, anxiety, insomnia

TRANSDERMAL:

• Frequency not reported: Anxiety, insomnia^[Ref]

Hematologic

ORAL:

• Common (1% to 10%): Anemia, leukopenia, thrombocytopenia

PARENTERAL:

• Common (1% to 10%): Anemia, leukopenia, thrombocytopenia

TRANSDERMAL:

• Frequency not reported: Anemia, leukopenia, thrombocytopenia^[Ref]

Dermatologic

ORAL:

• Common (1% to 10%): Alopecia
• Uncommon (0.1% to 1%): Rash/skin rashes, urticaria

PARENTERAL:

• Common (1% to 10%): Alopecia, rash/skin rashes
• Uncommon (0.1% to 1%): Urticaria

TRANSDERMAL:

• Frequency not reported: Alopecia, rash, urticaria^[Ref]

Cardiovascular

ORAL:

• Common (1% to 10%): Hypertension
• Uncommon (0.1% to 1%): QT prolongation
• Rare (0.01% to 0.1%): Angina pectoris, arrhythmias, atrial fibrillation, ECG abnormalities, hypotension, non-sustained tachycardia, sinus bradycardia, varying degrees of atrioventricular (AV) block, ventricular ectopy

PARENTERAL:

• Common (1% to 10%): Hypertension
• Uncommon (0.1% to 1%): QT prolongation
• Rare (0.01% to 0.1%): Angina pectoris, arrhythmias, atrial fibrillation, ECG abnormalities, hypotension, non-sustained tachycardia, sinus bradycardia, varying degrees of AV block, ventricular ectopy
• Frequency not reported: Flushing
• Postmarketing reports: Bradycardia, chest pain, palpitations, sick sinus syndrome

TRANSDERMAL:

• Common (1% to 10%): QT prolongation
• Uncommon (0.1% to 1%): Flushing, generalized edema
• Rare (0.01% to 0.1%): Angina pectoris, atrial fibrillation, hypertension, hypotension
• Postmarketing reports: Bradycardia, chest pain, palpitations, sick sinus syndrome^[Ref]

Metabolic

ORAL:

• Common (1% to 10%): Decreased appetite

PARENTERAL:

• Common (1% to 10%): Decreased appetite

TRANSDERMAL:

• Uncommon (0.1% to 1%): Decreased appetite^[Ref]

Hypersensitivity

ORAL:

• Uncommon (0.1% to 1%): Anaphylaxis, hypersensitivity reactions
• Rare (0.01% to 0.1%): Severe hypersensitivity reactions

PARENTERAL:

• Uncommon (0.1% to 1%): Anaphylaxis, hypersensitivity reactions

TRANSDERMAL:

• Frequency not reported: Anaphylaxis, hypersensitivity reactions/severe hypersensitivity reactions^[Ref]

Respiratory

ORAL:

• Uncommon (0.1% to 1%): Shortness of breath

PARENTERAL:

• Rare (0.01% to 0.1%): Shortness of breath

TRANSDERMAL:

• Rare (0.01% to 0.1%): Shortness of breath^[Ref]

Musculoskeletal

TRANSDERMAL:

• Uncommon (0.1% to 1%): Arthralgia^[Ref]

Further information

Granisol side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer